Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test

JJ. Michiels, P. Smejkal, M. Penka, A. Batorova, T. Pricangova, U. Budde, I. Vangenechten, A. Gadisseur,

. 2017 ; 23 (6) : 518-531. [pub] 20160721

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18025344

The European Clinical Laboratory and Molecular (ECLM) classification of von Willebrand disease (vWD) is based on the splitting approach which uses sensitive and specific von Willebrand factor (vWF) assays with regard to the updated molecular data on structure and function of vWF gene and protein defects. A complete set of FVIII:C and vWF ristocetine cofactor, collagen binding, and antigen, vWF multimeric analysis in low- and medium-resolution gels, and responses to desmopressin (DDAVP) of FVIII:C and vWF parameters are mandatory. The ECLM classification distinguishes recessive types 1 and 3 vWD from recessive vWD 2C due to mutations in the D1 and D2 domains and vWD 2N due to mutations in the D'-FVIII-binding domain of vWF. The ECLM classification differentiates between mild vWD type 1 with variable penetrance of bleedings from symptomatic dominant type 1 vWD secretion defect and/or clearance defect with normal vWF multimers versus vWD 1M and 2M with normal or smeary vWF multimers in low- and medium-resolution gels. High-quality multimeric analysis of vWF in medium-resolution gels based on a DDAVP challenge test clearly delineates and distinguishes each of the dominant type 2 vWDs 1/2E, 2M, 2B, 2A, and 2D caused by vWF gene mutations in the D3 multimerization domain, loss or gain-of-function mutations in the glycoprotein Ib receptor A1 domain, gene mutations in the A2 proteolytic domain, and the C-terminal dimerization domain, respectively.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025344
003      
CZ-PrNML
005      
20180713102621.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1076029616647157 $2 doi
035    __
$a (PubMed)27443694
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Michiels, Jan Jacques $u 1 Goodheart Institute in Nature Medicine & Health, Blood Coagulation and Vascular Medicine Center, Rotterdam, The Netherlands. 2 Hemostasis Research Unit, Department of Hematology, Antwerp University Hospital, Belgium.
245    10
$a Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test / $c JJ. Michiels, P. Smejkal, M. Penka, A. Batorova, T. Pricangova, U. Budde, I. Vangenechten, A. Gadisseur,
520    9_
$a The European Clinical Laboratory and Molecular (ECLM) classification of von Willebrand disease (vWD) is based on the splitting approach which uses sensitive and specific von Willebrand factor (vWF) assays with regard to the updated molecular data on structure and function of vWF gene and protein defects. A complete set of FVIII:C and vWF ristocetine cofactor, collagen binding, and antigen, vWF multimeric analysis in low- and medium-resolution gels, and responses to desmopressin (DDAVP) of FVIII:C and vWF parameters are mandatory. The ECLM classification distinguishes recessive types 1 and 3 vWD from recessive vWD 2C due to mutations in the D1 and D2 domains and vWD 2N due to mutations in the D'-FVIII-binding domain of vWF. The ECLM classification differentiates between mild vWD type 1 with variable penetrance of bleedings from symptomatic dominant type 1 vWD secretion defect and/or clearance defect with normal vWF multimers versus vWD 1M and 2M with normal or smeary vWF multimers in low- and medium-resolution gels. High-quality multimeric analysis of vWF in medium-resolution gels based on a DDAVP challenge test clearly delineates and distinguishes each of the dominant type 2 vWDs 1/2E, 2M, 2B, 2A, and 2D caused by vWF gene mutations in the D3 multimerization domain, loss or gain-of-function mutations in the glycoprotein Ib receptor A1 domain, gene mutations in the A2 proteolytic domain, and the C-terminal dimerization domain, respectively.
650    _2
$a desmopresin $x farmakologie $7 D003894
650    12
$a diferenciální diagnóza $7 D003937
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a multimerizace proteinu $7 D055503
650    _2
$a von Willebrandova nemoc, typ 1 $x diagnóza $7 D056725
650    _2
$a von Willebrandova nemoc, typ 2 $x diagnóza $7 D056728
650    _2
$a von Willebrandův faktor $x analýza $x genetika $7 D014841
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Smejkal, Petr $u 3 Department of Clinical Hematology, University Hospital, Masaryk University, Brno, Czech Republic. 4 Faculty of Medicine, Department of Laboratory Methods, Masaryk University, Brno, Czech Republic.
700    1_
$a Penka, Miroslav $u 3 Department of Clinical Hematology, University Hospital, Masaryk University, Brno, Czech Republic. 4 Faculty of Medicine, Department of Laboratory Methods, Masaryk University, Brno, Czech Republic.
700    1_
$a Batorova, Angelika $u 5 Department of Hemostasis and Thrombosis, National Hemophilia Center, Medical School of Comenius University, Bratislava, Slovakia.
700    1_
$a Pricangova, Tatiana $u 5 Department of Hemostasis and Thrombosis, National Hemophilia Center, Medical School of Comenius University, Bratislava, Slovakia.
700    1_
$a Budde, Ulrich $u 6 Central Laboratory, Asklepios Kliniken, Hamburg, Germany.
700    1_
$a Vangenechten, Inge $u 2 Hemostasis Research Unit, Department of Hematology, Antwerp University Hospital, Belgium. 8 Hemostasis Research Unit, Antwerp University Hospital, Antwerp, Belgium.
700    1_
$a Gadisseur, Alain $u 2 Hemostasis Research Unit, Department of Hematology, Antwerp University Hospital, Belgium. 7 Department of Hematology, Antwerp University Hospital, Antwerp, Belgium. 8 Hemostasis Research Unit, Antwerp University Hospital, Antwerp, Belgium.
773    0_
$w MED00001108 $t Clinical and applied thrombosis/hemostasis official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis $x 1938-2723 $g Roč. 23, č. 6 (2017), s. 518-531
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27443694 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180713102915 $b ABA008
999    __
$a ok $b bmc $g 1317475 $s 1022265
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 23 $c 6 $d 518-531 $e 20160721 $i 1938-2723 $m Clinical and applied thrombosis/hemostasis $n Clin Appl Thromb Hemost $x MED00001108
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...